The general anaesthetic etomidate inhibits the excitability of mouse thalamocortical relay neurons by modulating multiple modes of GABA_A receptor-mediated inhibition

Herd, Murray B.; Lambert, Jeremy J.; Belelli, Delia

Published in:
European Journal of Neuroscience

DOI:
10.1111/ejn.12601

Publication date:
2014

Licence:
CC BY

Document Version
Publisher's PDF, also known as Version of record

Link to publication in Discovery Research Portal

Citation for published version (APA):
Herd, M. B., Lambert, J. J., & Belelli, D. (2014). The general anaesthetic etomidate inhibits the excitability of mouse thalamocortical relay neurons by modulating multiple modes of GABA_A receptor-mediated inhibition. European Journal of Neuroscience, 40(3), 2487-501. https://doi.org/10.1111/ejn.12601

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 04. Nov. 2023
The general anaesthetic etomidate inhibits the excitability of mouse thalamocortical relay neurons by modulating multiple modes of GABAₐ receptor-mediated inhibition

Murray B. Herd, Jeremy J. Lambert and Delia Belelli
Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK

Abstract
Modulation of thalamocortical (TC) relay neuron function has been implicated in the sedative and hypnotic effects of general anaesthetics. Inhibition of TC neurons is mediated predominantly by a combination of phasic and tonic inhibition, together with a recently described ‘spillover’ mode of inhibition, generated by the dynamic recruitment of extrasynaptic γ-aminobutyric acid (GABAₐ) receptors (GABAₐRs). Previous studies demonstrated that the intravenous anaesthetic etomidate enhances tonic and phasic inhibition in TC relay neurons, but it is not known how etomidate may influence spillover inhibition. Moreover, it is unclear how etomidate influences the excitability of TC neurons. Thus, to investigate the relative contribution of synaptic (α₁β₂γ₂) and extrasynaptic (α₄β₂δ) GABAₐRs to the thalamic effects of etomidate, we performed whole-cell recordings from mouse TC neurons lacking synaptic (α₁₀β₂δ) or extrasynaptic (δ₀β₂δ) GABAₐRs. Etomidate (3 μM) significantly inhibited action-potential discharge in a manner that was dependent on facilitation of both synaptic and extrasynaptic GABAₐRs, although enhanced tonic inhibition was dominant in this respect. Additionally, phasic inhibition evoked by stimulation of the nucleus reticularis exhibited a spillover component mediated by δ-GABAₐRs, which was significantly prolonged in the presence of etomidate. Thus, etomidate greatly enhanced the transient suppression of TC spike trains by evoked inhibitory postsynaptic potentials. Collectively, these results suggest that the deactivation of thalamus observed during etomidate-induced anaesthesia involves potentiation of tonic and phasic inhibition, and ilmplicate amplification of spillover inhibition as a novel mechanism to regulate the gating of sensory information through the thalamus during anaesthetic states.

Introduction
The ability of general anaesthetics to impair consciousness, and induce analgesia, amnesia and immobility, has been exploited clinically for over a century (Rudolph & Antkowiak, 2004). Yet, despite their routine clinical use, the neuroanatomical substrates of anaesthetic actions remain enigmatic, with several components of the circuitry regulating the sleep–wake cycle implicated to date (Franks, 2008). Nevertheless, electrophysiological, neuroimaging and modelling studies consistently pinpoint the thalamus as an important neural locus for anaesthetic-induced hypnosis (Angel, 1991; Fiset et al., 1999; Alkire et al., 2000; White & Alkire, 2003; Ching et al., 2010; Andrade et al., 2012). Such observations are consistent with the classical role of the thalamus in controlling transitions between conscious states (Steriade et al., 1993).

At the cellular level, γ-aminobutyric acid (GABAₐ) receptors (GABAₐRs) represent key molecular targets for several general anaesthetics, including the intravenous agents etomidate and propofol (Hales & Lambert, 1991; Orser et al., 1994; Uchida et al., 1995). Importantly, anaesthetic-induced modulation of inhibition may be influenced by the molecular identity of GABAₐRs (Belelli et al., 1996; Bonin & Orser, 2008), which are composed of five subunits drawn from a pool of 19 isoforms (Olsen & Sieghart, 2009). Etomidate is unique in this respect, displaying selectivity for β₂- or β₃-containing receptors vs. those incorporating the β₁ subunit (Hill-Venning et al., 1997). Subunit composition additionally influences the functional properties and spatiotemporal expression of GABAₐRs. Thus, synaptic GABAₐRs, which mediate brief phasic inhibition, are composed of α₂β₂γ₂ subunits, whereas receptors incorporating a δ rather than a γ₂ subunit, are localized to extra- or peri-synaptic locations, and mediate persistent tonic inhibition (Farrant & Nusser, 2005). However, a substantial number of GABAₐRs with a typically ‘synaptic’ subunit composition also exist extrasynaptically, although the functional role of such receptors remains to be established (Kasugai et al., 2010). δ-GABAₐRs have been proposed as important general anaesthetic targets, a suggestion supported by their abundant expression in brain regions implicated in some anaesthetic behaviours, including thalamocortical (TC) relay
nuclei (Belelli et al., 2005; Jia et al., 2005). However, while etomidate enhances both phasic and tonic currents recorded from TC neurons (Belelli et al., 2005), it is unknown how these respective actions influence the excitability of relay neurons.

Recently, we demonstrated that in addition to generating tonic inhibition, δ-GABAARs of TC neurons may be recruited via a spillover-like mechanism to prolong phasic inhibition generated in response to presynaptic spike bursts (Herd et al., 2013). This observation may have particular relevance to anaesthetic effects in thalamus, given that nucleus reticularis thalami (nRT) neurons, which provide the major source of GABA-ergic innervation to TC neurons, exhibit prominent spike bursts during unconscious states. Whether and how anaesthetics may influence this ‘burst-mediated spillover’ mode is not known.

Here, we investigated the relative contribution of synaptic and extrasynaptic GABAARs to the inhibitory effects of etomidate on relay neuron output. Using transgenic mice in which TC relay neurons lack synaptic (z1100, Peden et al., 2008) or extrasynaptic (δ100, Herd et al., 2009) GABAARs, we report that, although enhancement of tonic inhibition dominates the inhibitory effect of etomidate on TC neuron excitability, the synaptic z11β2 GABAAR population also significantly influences the effects of the anaesthetic. Moreover, we demonstrate that etomidate greatly prolongs burst-mediated spillover inhibition, providing a novel mechanism whereby a putatively relevant network may be influenced by anaesthetics.

Materials and methods

Use of z1100 and δ100 mice as models to investigate the thalamic effects of etomidate

Compensatory adaptations represent a significant caveat to the interpretation of experiments utilizing constitutive knockout mice. Indeed, biochemical and immunohistochemical evidence revealed compensatory up-regulation of x2 and/or x3 subunits in the neocortex and cerebellum of z1100 mice (Sur et al., 2001; Kralic et al., 2002a,b). However, in the thalamus of z1100 mice, the ablated x1 subunits are not replaced by x2 or x3 subunits (Kralic et al., 2006) and x3 expression remains unaltered in the presynaptic nRT (Kralic et al., 2006). Thus, at the functional level, the lack of any clear upregulation of the remaining palette of GABAAR subunits is reflected by a complete lack of miniature inhibitory postsynaptic currents (mIPSCs) in mature ventrobasal (VB) neurons, but unaltered mIPSC properties in the nRT (Peden et al., 2008). Moreover, extrasynaptic GABAARs do not appear to compensate for the lost phasic inhibition, as tonic inhibition is not significantly altered in z1100 VB neurons, at least at the limited age range studied here (Herd et al., 2009). In the δ100 mouse (Mihalek et al., 1999), increased expression of γ2 subunits has been reported (Tretter et al., 2001; Peng et al., 2002). Importantly, however, receptors incorporating x1, x2, x3 or x5 subunits do not appear to substitute for the lost δ-containing receptors (Peng et al., 2002). In agreement, we did not observe any clear alterations in the properties of relay neuron mIPSCs that could compensate for the greatly reduced tonic inhibition in δ100 mice (Herd et al., 2009). Thus, the lack of clear adaptive changes in the properties of phasic and tonic inhibition at the thalamic level in the z1100 and δ100 mice validates their utility as models to investigate the influence of etomidate on relay neuron excitability.

The z1100 and δ100 mice were generated on a mixed C57BL6/129SvEv (z1100) or single C57BL6 (δ100) background at the Merck Research Laboratories at the Neuroscience Research Centre in Harlow and at the University of Pittsburgh, respectively, as described previously (Mihalek et al., 1999; Sur et al., 2001). Brain slices were prepared from the first two generations of z1100 and δ100 and their respective wild-type (WT) mice from breeding pairs derived from the corresponding heterozygous mice bred at the University of Dundee. Measures of inhibition (phasic and tonic) and neuronal excitability [input resistance (IR) and action potential rheobase] did not differ between z1100 and δ100 (data not shown). Results obtained from the respective WT strains were thus pooled.

Slice preparation

Animals were killed by cervical dislocation in accordance with Schedule 1 of the UK Government Animals (Scientific Procedures) Act 1986. Thalamic slices were prepared from mice of either sex (postnatal days 16–24) according to standard protocols (Herd et al., 2009). Dissected brains were sliced horizontally (300–350 μm) in an ice-cold surose-based cutting solution, using a Leica VT1000S vibratome (Nussloch, Germany). The slices were incubated at room temperature (20–23 °C) for a minimum of 1 h prior to recording in an oxygenated, extracellular solution (ECS) containing (in mM): 126 NaCl, 2.95 KCl, 1.25 NaH2PO4, 2 CaCl2, 10 D-glucose and 2 MgCl2 (pH 7.4; 300–310 mOsm).

Electrophysiology

Electrophysiological recordings were performed from thalamic slices maintained in warmed ECS (30 °C), using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA, USA). Thalamocortical relay neurons of the VB complex were visually identified with an Olympus BX51 microscope (Olympus, Southall, UK), equipped with differential interference contrast/infrared optics and a charge-coupled device camera. Whole-cell voltage- and current-clamp recordings from VB neurons were obtained using patch pipettes prepared from thick-walled borosilicate glass (King Precision Glass, Claremont, CA, USA) using a Narishige PC-10 vertical puller, and had open tip resistances of 4–6 MΩ when filled with a solution containing (in mM): 130 K-glucosone, 2 KCl, 2 NaCl, 10 HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 0.2 EGTA (ethylenediaminetetraacetic acid), 2 Mg adenosine triphosphate, 0.5 Na guanosine-5’-triphosphate, 10 Tris-phosphocreatine, adjusted to pH 7.2–7.3 with KOH, 280–290 mOsm. Series resistance was intermittently monitored, compensated for (up to 80% for voltage-clamp, 100% for current-clamp) and recordings discarded if values changed by more than 25%, or increased beyond 25 MΩ. Voltage-clamp recordings were performed at a holding potential of −50 mV (GABA Erev ~−85 mV), and thus responses mediated by GABAARs were outwardly directed. Inhibitory responses were evoked in VB neurons using a bipolar tungsten electrode (World Precision Instruments, Stevenage, UK), placed within the borders of the nRT. Stimuli were delivered (20-μs duration, 0.1 Hz) using a Digitimer DS3 Isolated Stimulator (Digitimer, Welwyn Garden City, UK), with stimulus intensity adjusted to the minimum value that avoided failures, but still generated IPSC bursts of relatively consistent amplitude (i.e. for each recording, the excitatory IPSC (eIPSC) peak amplitude standard deviation (SD) was <15% of the mean peak amplitude obtained from that cell; WT = 8.5 ± 1.4%, n = 7; z1100 = 10.5 ± 1.4%, n = 7; δ100 = 8.9 ± 0.8%). At the stimulation intensities utilized, the number of peaks observed in response to each stimulus was relatively consistent from trial to trial (SD = 0.94 and 1.30 for WT and δ100, respectively). Although we find GABAAR activation is minimal under these recording conditions/stimulation parameters (data not shown), we performed the experiments in the presence of GP 55845 (1 μM) to block GABAARs. Holding currents (Ihold) were
continuously monitored throughout voltage-clamp recordings to determine the effect of etomidate on tonic inhibition. Current-clamp recordings were also performed to determine the effect of burst-mediated inhibition on VB neuron spiking. Thus, evoked inhibitory postsynaptic potentials (eIPSPs) were evoked at regular intervals (0.09–0.11 Hz) during tonic trains of action potentials. Tonic spike trains were generated by depolarizing the recorded neuron to a supra-threshold membrane potential (V_m) using depolarizing direct current (DC) injection delivered via the recording electrode. The amplitude of injected DC was carefully adjusted to maintain a tonic spike frequency of ~4–8 Hz. In this paradigm, eIPSPs generated a transient cessation of action potential discharge. eIPSPs were also recorded at or near the resting potential, and in some cells a rebound low-threshold Ca^{2+} potential was observed, which was commonly crowned by a high-frequency spike burst. In such recordings, the latency to rebound, relative to eIPSP onset, was determined for each event before and after etomidate application. VB neuron excitability was also examined in current-clamp experiments by monitoring action potential output in response to a family of current steps. The stimulation protocol consisted of a set of hyperpolarizing and depolarizing current pulses (~200 to +300 pA, 400-ms duration, in increments of 50 pA, every 15 s), delivered via the recording electrode before and after the bath application of etomidate. Current stimulations were delivered from a holding potential of ~66 mV to isolate the tonic spike mode during depolarizing stimulations. The number of action potentials generated in response to positive current steps, and within low-threshold Ca^{2+} current (I_t)-mediated rebound bursts following release from hyperpolarization, were counted for each condition. Membrane IR was calculated according to Ohm’s law following delivery of small (~20 pA, 300 ms) hyperpolarizing current steps from the resting membrane potential. A measured liquid junction potential of 11 mV was corrected offline. Recordings were filtered at 2 or 5 kHz for voltage- and current-clamp recordings, respectively, and acquired directly to PC using a NI-DAQmx analog-to-digital interface (National Instruments UK, Newbury, UK) for subsequent offline analysis.

Data analysis
All electrophysiological data were analysed offline using the Strathclyde Electrophysiology software, WinEDR/WinCWP (J. Dempster, University of Strathclyde, UK) software package. For voltage-clamp experiments, eIPSCs were analysed with respect to peak amplitude, 10–90% rise times and charge transfer. The decay time course following the final peak of multi-peak eIPSCs was adequately described by fitting a double exponential function \( y(t) = A_1e^{(-t/\tau_1)} + A_2e^{(-t/\tau_2)} \) using the least squares method, where \( A \) is amplitude, \( t \) is time and \( \tau \) is the decay time constant. Analysis of the SD of residuals and use of the F-test was used to compare goodness of fit, confirming an improved fit of the decay was achieved when employing a double- rather than a mono-exponential function. Thus, a weighted decay time constant (\( \tau_w \)) was also calculated according to the equation, \( \tau_w = \tau_1P_1 + \tau_2P_2 \), where \( \tau_1 \) and \( \tau_2 \) are the decay time constants of the first and second exponential functions and \( P_1 \) and \( P_2 \) are the proportions of the synaptic current decay described by each component. To determine the effect of etomidate on VB tonic inhibition, etomidate-induced outward shifts of the holding current (\( I_{hold} \)) were quantified by sampling sequential 51.2-ms epochs for a 2-min period before, and after application of etomidate (Belelli et al., 2005). Epochs containing evoked or spontaneous synaptic currents were excluded. The mean holding current in each condition was determined from Gaussian fits to the distribution of holding current values sampled from each epoch.

For current-clamp experiments investigating the effect of etomidate on VB neuron excitability, input-output curves were constructed by plotting the number of action potentials generated as a function of stimulus amplitude. To quantify etomidate-induced shifts in input–output curves, data were fit with a Boltzmann sigmoidal curve according to the equation \( y(x) = N_{\text{max}}/1 + e^{y(x) - X_{50}}/S \), where \( N_{\text{max}} \) is the number of action potentials generated at the maximum stimulus amplitude (in this case 300 pA), \( X \) is the stimulus amplitude, \( X_{50} \) is the stimulus amplitude producing half-maximal spike output (hereafter ‘EA50’) and S is the slope factor. For experiments investigating the effect of eIPSPs on tonic spike trains, inter-spike intervals (ISIs) were measured throughout the spike train. For baseline measurements, ISIs were determined for a 5-s period preceding each eIPSP (minimum of three stimulations) to ensure spike rates recovered to stable frequencies following inhibition. The ISI during an IPSP was simply the interval between the final spike prior to delivery of an eIPSP and the first spike following recovery from inhibition. The transient suppression of tonic spike activity induced by an eIPSP was observed as an immediate and obvious increase in the ISI (see Figs 2 and 3).

All results are reported as the arithmetic mean ± standard error of the mean (SEM). Statistical significance of the mean data was assessed with a Student’s t test (paired, or unpaired), one-way analysis of variance (ANOVA) or a two-way mixed-design ANOVA as appropriate, using the SPSS (SPSS Inc., Chicago, IL USA) software package. Sphericity was assessed with Mauchly’s test, and degrees of freedom were adjusted using a Greenhouse–Geisser correction if sphericity was violated. Post-hoc multiple comparisons were conducted using Tukey’s test. Unless explicitly stated, statistical significance was assessed using Student’s t-test. Boltzmann curve fits were performed in Origin v7 (OriginLab, Northampton, MA, USA).

Salts and drugs
R-(+) etomidate (supplied by Merck, Glasgow, UK) was prepared as a concentrated aqueous stock and diluted 1000-fold in ECS to a final concentration of 3 μm. CGP 55835 (Abcam, Cambridge, UK) was prepared in dimethyl sulphoxide (DMSO) as a 1000-fold concentrated stock solution and diluted in ECS to the final desired concentration. The final DMSO concentration (0.1%) had no effect on any of the measured parameters (data not shown). Etomidate was applied via the perfusion system (2–4 μL/min) and allowed to infiltrate the slice for a minimum of 10 min. All other salts and drugs were obtained either from Sigma-Aldrich (Poole, UK), Tocris Bioscience (Bristol, UK) or VWR (Lutterworth, UK).

Results

Etomidate prolongs eIPSCs by potentiating synaptic and extrasynaptic GABA_ARs
In VB neurons, etomidate prolongs mIPSCs and enhances tonic currents mediated by GABA_ARs and GABA_BRs, respectively (Belelli el al., 2005). However, our recent demonstration that thalamic δ-GABA_ARs may influence the kinetics of action potential-dependent phasic inhibition, particularly in response to spike bursts (Herd et al., 2013), provides an additional route whereby etomidate may influence VB inhibition. Thus, we investigated the effects of etomidate on electrically evoked IPSCs generated in response to extracellular stimulation of the nRT of WT, GABA_ARs and GABA_BRs mouse brain slices.

In voltage-clamp recordings utilising K+-gluconate-based pipette solutions (GABA_ARs, ~85 mV, GABA_BRs, ~50 mV), extracellular stimulation of the nRT in WT brain slices generated outwardly...
directed eIPSCs composed of multiple peaks, and a bi-exponential decay phase following the final peak (Table 1, Fig. 1A). The multi-peak nature of the eIPSCs is consistent with the generation of T-dependent spike bursts in presynaptic neurons. Application of etomidate (3 μM) greatly increased the eIPSC peak amplitude (Table 2, Fig. 1A and D, n = 7, P < 0.001), and τw (Table 2, Fig. 1A and E, P < 0.001), resulting in a significant enhancement of eIPSC charge transfer (Table 2, Fig. 1A and F, P = 0.001). Consistent with our previous report (Herd et al., 2013), robust residual eIPSCs were recorded from z100 mice, despite the absence of synaptic GABAARs (Table 1, Fig. 1B). The slow kinetics of the rising and decaying phase of z100 eIPSCs, together with their sensitivity to modulation by the δ-selective competitive DS2 (Wafford et al., 2009; Herd et al., 2013; Jensen et al., 2013), indicate that such residual events are mediated by recruitment of δ-containing extrasynaptic (e)GABAARs in response to nRT spike bursts. Importantly, acute application of etomidate greatly enhanced the peak amplitude (Table 2, Fig. 1B and D, n = 7, P < 0.001) and τw (Table 2, Fig. 1B and E, P < 0.001) of z100 eIPSCs, leading to a significant increase in their charge transfer (Table 2, Fig. 1F, P < 0.001). However, the overall effect of etomidate on eIPSC charge transfer was reduced for z100 relative to WT neurons (Fig. 1F, drug × genotype interaction, F2,19 = 7.21, P = 0.005, mixed ANOVA), suggesting that a significant proportion of the effects of etomidate on WT eIPSCs are mediated by synaptic GABAARs. In support, etomidate also enhanced eIPSCs recorded from δ000 neurons (Fig. 1C). In agreement with previous findings (Herd et al., 2013), eIPSCs recorded from δ000 mice exhibited faster decay kinetics, due to the abolished eGABAAR component normally engaged by neurally released GABA acting on WT neurons (Table 1). Nevertheless, despite the absence of the eGABAAR contribution to eIPSC properties, etomidate (3 μM) significantly increased eIPSC peak amplitude (Table 2, Fig. 1C and D, n = 8, P = 0.003), τw (Table 2, Fig. 1C and E, P < 0.001) and charge transfer (Table 2, Fig. 1F, P = 0.003). However, as observed for z100 recordings, deletion of the δ subunit significantly reduced the overall effect of etomidate on eIPSC charge transfer relative to WT (Fig. 1F, drug × genotype interaction, F2,19 = 7.21, P = 0.005, mixed ANOVA).

### Table 1. Comparison of eIPSC properties recorded from WT, z100 and δ000 mice

|          | WT (n = 16) | z100 (n = 14) | δ000 (n = 10) |
|----------|------------|--------------|--------------|
| No. of peaks/eIPSC | 7.6 ± 0.4 | 7.2 ± 0.4 | 7.2 ± 0.4 |
| Mean frequency of peaks/eIPSC (Hz) | 269.8 ± 16.2 | 270.9 ± 14.0 | 270.9 ± 14.0 |
| Peak amplitude (pA) | 604.1 ± 70.7 | 142.9 ± 22.7 | 493.2 ± 58.6 |
| Rise Time to 1st peak (ms) | 1.1 ± 0.2 | 12.46 ± 0.9** | 1.1 ± 0.1 |
| Charge transfer (pC) | 39.0 ± 5.5 | 11.5 ± 2.1** | 16.1 ± 2.3** |
| τm (ms) | 28.2 ± 1.7 | 46.2 ± 6.0** | 17.6 ± 1.0** |
| τf (ms) | 28.2 ± 2.5 | 44.9 ± 5.8** | 9.9 ± 0.7** |
| No. of peaks/eIPSC | 219.0 ± 18.8 | 233.9 ± 19.8 | 50.8 ± 3.5** |
| % τw | 82.0 ± 3.6 | 84.8 ± 2.9 | 72.5 ± 2.3 |
| τw (ms) | 58.3 ± 6.3 | 76.3 ± 11.3 | 21.5 ± 2.1** |

*P < 0.05, **P < 0.01, ***P < 0.001 vs. WT, one-way ANOVA, Tukey’s post-hoc test. N/D, not determined.

**Etidomide prolongs phasic suppression of VB tonic firing and delays post-inhibitory rebound burst firing**

During conscious brain states, thalamocortical relay neurons exist in a relatively depolarized state, and respond to incoming excitatory inputs in the tonic ‘relay’ mode (Steriade et al., 1993). Given the shared roles of synaptic and extrasynaptic GABAARs in regulating the kinetics of inhibitory synaptic transmission (see above), we hypothesized that these receptor populations should combine to regulate the effect of etomidate on phasic inhibition of tonic VB spike output.

To explore these questions, we performed whole-cell current-clamp recordings of tonic firing from WT, z100 and δ000 slices. VB neurons were slowly depolarized from the resting membrane potential (Table 3) by DC injection until they discharged trains of tonic spikes, occurring at ~4–8 Hz (mean spike frequency: WT: 5.8 ± 0.3 Hz, n = 13; z100: 5.7 ± 0.3 Hz, n = 12; δ000: 5.5 ± 0.1 Hz, n = 8; F2,32 = 0.35, P = 0.71, one-way ANOVA). We then evoked IPSPs by extracellular stimulation of the nRT (0.09–0.11 Hz stimulation frequency) at regular intervals during the tonic train, and quantified the duration of the eIPSP-induced suppression of tonic firing across strains (i.e. ISI), before and after etomidate (3 μM) (Figs 2 and 3). As illustrated in the representative example in Fig. 2A, stimulation of the nRT in WT brain slices evoked reproducible IPSPs, which transiently suppressed tonic spiking of VB neurons (baseline ISI = 173 ± 8 ms; ISI during IPSP = 1106 ± 118 ms; n = 13, P < 0.001; Fig. 2D). Remarkably, despite the absence of a detectable synaptic receptor population in VB, equivalent stimulation of the nRT in z100 slices generated eIPSPs that transiently inhibited tonic spiking, albeit to a lesser extent than in WT tissue (baseline ISI = 176 ± 10 ms; ISI during IPSP = 672 ± 67 ms; n = 12, P < 0.001; stimulation × genotype interaction, F2,28 = 7.04, P = 0.003, mixed ANOVA; Fig. 2B and D). Similarly, in δ000 slices, eIPSPs induced a reproducible blockade of VB tonic firing, although the duration of spike suppression was significantly (and similar to z100) reduced relative to WT recordings (baseline ISI = 180 ± 5 ms; ISI during IPSP = 650 ± 49 ms; n = 8, P < 0.001, stimulation × genotype interaction, F2,28 = 7.04, P = 0.003, mixed ANOVA; Fig. 2C and D), consistent with voltage-clamp experiments demonstrating faster eIPSC decay time in the absence of δ-GABAARs.

Consistent with the robust potentiation of eIPSCs observed in voltage-clamp experiments, etomidate (3 μM) significantly prolonged the duration of tonic firing suppression induced by eIPSPs in WT (ISI during IPSP: control = 1000 ± 148 ms; + etomidate = 1624 ± 161 ms; n = 8, P < 0.001; Fig. 3A and D), z100 (ISI during IPSP: control = 737 ± 67 ms; + etomidate = 1383 ± 78 ms; n = 9, P < 0.001; Fig. 3B and D) and δ000 brain slices (ISI during IPSP: control = 670 ± 54 ms; + etomidate = 1427 ± 206 ms; n = 6, P < 0.001; Fig. 3C and D). Surprisingly, however, the effect of etomidate on eIPSP-induced suppression of tonic firing (i.e. the difference in ISI during an IPSP before and after etomidate application) was not significantly different between strains (Fig. 3D, F2,20 = 0.56, P = 0.58, mixed ANOVA), despite the ablation of either major subcellular populations of GABAARs.

In a subset of these recordings, eIPSPs recorded at or slightly depolarized to the resting membrane potential were of sufficient amplitude to generate a rebound low-threshold Ca2+ potential and associated spike burst at the offset of the eIPSP (von Krosigk et al., 1993). We therefore investigated the effect of etomidate on the post-inhibitory rebound properties by measuring the latency to rebound. Consistent with the prolongation of evoked phasic inhibition, etomidate significantly delayed the timing of rebound bursts in WT recordings (Fig. 4A and C, n = 4, P = 0.009) at similar Vm (pre-eIPSP Vm = -68.3 ± 1.2 and -69.0 ± 1.2 mV for control and etomidate, respectively). Similarly, in δ000 recordings, the latency to post-inhibitory rebound was significantly increased in the presence of etomidate (Fig. 4B and C, n = 5, P < 0.001) at equivalent Vm (pre-eIPSP...
FIG. 1. Etomidate prolongs the duration of evoked phasic inhibition in VB neurons by potentiating synaptic and extrasynaptic GABA_A receptors. (A–C) Superimposed, representative, evoked IPSCs recorded from WT (A), α^100 (B) and δ^00 (C) VB neurons under control conditions (black) and in the presence of 3 μM etomidate (grey). Currents were evoked by extracellular stimulation of the nRT (single shocks, 20 μs duration). (D–E) Bar graphs illustrating the effect of etomidate on eIPSC peak amplitude (D), t_w (E) and charge transfer (F) in WT (black bars, n = 7), α^100 (dark grey bars, n = 7) and δ^00 (light grey bars, n = 8) thalamic slices. **P < 0.01, ***P < 0.001 vs. control, paired t-test. ††P < 0.01 vs. WT, mixed ANOVA, Tukey’s post-hoc test. Etom, etomidate.

TABLE 2. Comparison of the effect of etomidate on eIPSCs recorded from WT, α^100 and δ^00 mice

|                  | WT (n = 7) | α^100 (n = 7) | δ^00 (n = 8) |
|------------------|------------|---------------|--------------|
|                  | Control    | 3 μM etomidate | Control       | 3 μM etomidate | Control       | 3 μM etomidate |
| Peak amplitude (pA) | 599 ± 101  | 1037 ± 152*** | 198 ± 31     | 465 ± 40***   | 477 ± 73     | 740 ± 121**  |
|                  | 53 ± 7     | 144 ± 9***    | 73 ± 14      | 139 ± 20***   | 21 ± 3       | 93 ± 9***    |
|                   | 40 ± 8     | 184 ± 32**    | 17 ± 3       | 76 ± 8***     | 16 ± 3       | 81 ± 17***   |

**P < 0.01, ***P < 0.001, paired t-test.
Table 3. Comparison of resting membrane potential (V_m) and input resistance recorded from WT, α1100 and δ000 mice

|                  | WT (n = 38) | α1100 (n = 19) | δ000 (n = 27) |
|------------------|------------|---------------|---------------|
| V_m (mV)         | −72.5 ± 0.5| −72.0 ± 0.9   | −73.5 ± 0.5   |
| Input resistance (MΩ) | 288 ± 13  | 274 ± 22     | 328 ± 20     |

V_m = −67.8 ± 0.3 and −68.3 ± 0.2 mV for control and etomidate, respectively. eIPSPs recorded from α1100 slices did not elicit rebound bursts, although in all seven recordings, the duration of eIPSPs recorded from equivalent membrane potentials were prolonged (data not shown). These observations imply that both synaptic and extrasynaptic receptor modulation can influence post-inhibitory rebound timing.

Deletion of the α1 or δ subunit influences the etomidate-induced enhancement of the VB tonic current

While quantifying the effects of etomidate on eIPSCs, we simultaneously monitored the VB holding current in each mouse strain to further understand the contribution of α1βγ2 and α4βδ GABA<sub>A</sub>Rs

Fig. 2. Synaptic and extrasynaptic GABA<sub>A</sub>Rs influence phasic suppression of VB tonic firing. (A–C) Representative current-clamp recordings illustrating the suppression of tonic action potential discharge induced by evoked IPSPs in WT (A), α1100 (B) and δ000 (C) thalamic slices. The plots to the right of each trace depict the inter-spike interval (ISI) over the course of the illustrated recordings, and demonstrate the increase in ISI (i.e. spike suppression) during delivery of the eIPSP. Evoked IPSPs were generated by extracellular stimulation of the nRT. (D) Bar graph comparing the effect of eIPSPs on ISI during tonic spike trains recorded from WT (n = 13), α1100 (n = 12) and δ000 (n = 8) VB neurons. ***P < 0.001 vs. baseline ISI, paired t-test. †P < 0.05 vs. WT, mixed ANOVA, Tukey’s post hoc test.
Fig. 3. Etomidate prolongs phasic suppression of VB tonic firing by potentiating synaptic and extrasynaptic GABA\(_\text{A}\),Rs. (A–C) Whole-cell current-clamp recordings illustrating the suppression of VB tonic firing under control conditions (Ai–Ci), and in the presence of 3 \(\mu\)M etomidate (Aii–Cii), in WT (A), \(\alpha_{10/0}\) (B) and \(\delta_{0/0}\) (C) thalamic slices. The plots to the right of each trace depict the inter-spike interval (ISI) during the illustrated tonic spike train, and demonstrate blockade of action potentials during the eIPSP. Note that the ISI during the eIPSP is increased in the presence of etomidate across all mouse strains. (D) Bar graph comparing the effect of eIPSPs on the ISI of tonic spike trains, before and after etomidate, in WT (n = 8), \(\alpha_{10/0}\) (n = 9) and \(\delta_{0/0}\) (n = 6) VB neurons. The bar representations are depicted in the symbol key. ***\(P < 0.001\) vs. baseline ISI, paired \(t\)-test. +++\(P < 0.001\), ISI during eIPSP after etomidate application vs. control. The increased duration of the eIPSP-induced spike suppression observed in the presence of etomidate is not significantly influenced by mouse genotype (\(P = 0.58\), mixed ANOVA).
Fig. 4. Etomidate delays the timing of post-inhibitory rebound burst firing in VB neurons. (A, B) Exemplar traces from a subset of current-clamp recordings obtained from WT (A) and δ<sup>0</sup> (B) mice in which rebound burst firing was observed at the offset of eIPSPs. The responses to three consecutive stimuli recorded before (black traces) and after (grey traces) application of 3 μM etomidate are superimposed, illustrating the delay to rebound burst firing in the presence of the anaesthetic. Action potentials are truncated for clarity. (C) Summary bar graph comparing the latency to rebound spiking (black bars) and after etomidate (grey bars) application for WT (n = 4) and δ<sup>0</sup> (n = 5) VB neurons. **P < 0.01, ***P < 0.001, paired t-test.

to the effects of the anaesthetic on VB tonic inhibition. Bath application of 3 μM etomidate induced a clear outward shift in VB holding current (37.2 ± 5.0 pA, n = 8; Fig. 5A and G), with a time course similar to that observed for potentiation of eIPSCs (Fig. 5C and D). In recordings from VB neurons of δ<sup>0</sup> mice, bath application of 3 μM etomidate induced only a minimal outward current (5.0 ± 1.0 pA, n = 7; P < 0.001 vs. WT; P = 0.012 vs. δ<sup>0</sup>, mixed ANOVA). In recordings from VB neurons of δ<sup>0</sup> mice, bath application of 3 μM etomidate induced only a minimal outward current (5.0 ± 1.0 pA, n = 7; P < 0.001 vs. WT; P = 0.012 vs. δ<sup>0</sup>, mixed ANOVA). In recordings from VB neurons of δ<sup>0</sup> mice, bath application of 3 μM etomidate induced only a minimal outward current (5.0 ± 1.0 pA, n = 7; P < 0.001 vs. WT; P = 0.012 vs. δ<sup>0</sup>, mixed ANOVA). In recordings from VB neurons of δ<sup>0</sup> mice, bath application of 3 μM etomidate induced only a minimal outward current (5.0 ± 1.0 pA, n = 7; P < 0.001 vs. WT; P = 0.012 vs. δ<sup>0</sup>, mixed ANOVA).

**Deletion of z1 or δ subunits attenuates the effect of etomidate on VB neuron excitability**

Given that etomidate modulation of VB tonic inhibition is significantly reduced in δ<sup>0</sup> and δ<sup>0</sup> neurons, such genetic manipulations are thus predicted to influence the effect of the anaesthetic on cellular excitability. To investigate this hypothesis, we examined the effect of etomidate on VB input-output (I-O) relationships generated in response to a family of current steps (−200 to +300 pA, 400 ms duration, 50-pA increments every 15 s). Current steps were delivered while neurons were held at a membrane potential of −66 mV; at such potentials, I<sub>T</sub> is largely inactivated (Coulter et al., 1989). First, we compared I-O relationships across WT, z1<sup>0</sup> and δ<sup>0</sup> under control conditions to determine if basic electrical excitability was affected by the mutations (Fig. 5). Across all three strains, in accordance with classical TC neuron physiology, hyperpolarizing currents steps of sufficient amplitude generated a sagging, hyperpolarization-activated cation current (I<sub>h</sub>)-dependent membrane potential response, followed by a rebound low-threshold Ca<sup>2+</sup> potential, crowned by a high-frequency spike burst (spikes per burst, WT = 2–10, n = 3; δ<sup>0</sup> = 1–9, n = 12; δ<sup>0</sup> = 2–10, n = 22). Although the amplitude of the hyperpolarizing current step significantly influenced the mean number of spikes per rebound burst (F<sub>3,162</sub> = 104.80, P < 0.001, mixed ANOVA), there was no significant effect of genotype on this relationship (F<sub>5,612</sub> = 1.00, P = 0.43, mixed ANOVA, Fig. 6D). Supra-threshold depolarizing current steps of increasing amplitude generated tonic spikes of increasing frequency in VB neurons derived from each mouse strain (Fig. 6A–C and E). Although visual inspection of the resulting I-O curves (Fig. 6E) suggests a modest left-ward trend of the relationship towards increased excitability for δ<sup>0</sup> relative to WT recordings, this did not reach statistical significance (F<sub>2,215</sub> = 1.46, P = 0.20, mixed ANOVA). Indeed, estimation of the current amplitude generating half maximal spike output (EA<sub>50</sub>) from Boltzmann sigmoidal curve fits (see Methods) indicated a small, but non-significant effect of δ subunit deletion on the I-O EA<sub>50</sub> (WT = 173 ± 7 pA, n = 23; z1<sup>0</sup> = 168 ± 10 pA, n = 12; δ<sup>0</sup> = 158 ± 8 pA, n = 22, F<sub>2,54</sub> = 1.00, P = 0.37, one way ANOVA). Similarly, neither the resting membrane potential nor IR of VB neurons was significantly reduced by deletion of the δ subunit, although again a trend towards an increased IR was observed relative to WT (IR, WT = 288 ± 13 mΩ, n = 38; δ<sup>0</sup> = 328 ± 20 mΩ, n = 27, P = 0.1, unpaired t-test, Table 3).

In accordance with the large potentiation of tonic inhibition, bath application of 3 μM etomidate hyperpolarized the resting V<sub>m</sub>, reduced membrane IR and exerted a clear reduction in the excitability of WT VB neurons (Table 4, Fig. 7A–C). Thus, etomidate significantly reduced the number of spikes per rebound burst upon release from hyperpolarizing stimulations, although the effect was particularly evident for smaller amplitude current steps (Fig. 7A and B). Similarly, etomidate reduced the tonic spike output, resulting in a clear rightward shift of the I-O relationship of VB neurons (Fig. 7A and C). Indeed, the EA<sub>50</sub> determined from Boltzmann fits to I-O recordings (20.7 ± 2.9 pA, n = 9) concurrently with potentiation of residual eIPSCs (Fig. 5C and D), the magnitude of the outward current shift was significantly reduced relative to WT (Fig. 5G, drug × genotype interaction, F<sub>2,21</sub> = 20.11, P < 0.001, mixed ANOVA). In recordings from VB neurons of δ<sup>0</sup> mice, bath application of 3 μM etomidate induced only a minimal outward current (5.0 ± 1.0 pA, n = 7; P < 0.001 vs. WT; P = 0.012 vs. δ<sup>0</sup>, mixed ANOVA, Tukey’s post-hoc test; Fig. 5E and G), while robustly potentiating eIPSCs (Fig. 5F).
Fig. 5. Deletion of the α1 or δ subunit reduces the effect of etomidate on VB tonic inhibition. (A, C, E) Representative whole-cell recordings (left) and corresponding all points histograms (right), illustrating the effect of etomidate on the holding current of WT (A), α1100 (C) and δ00 (E) VB neurons. Evoked IPSCs were simultaneously monitored throughout the recordings, but have been truncated to emphasize changes in holding current (I_{hold}). Non-truncated eIPSCs denoted by i (control) and ii (etomidate) are shown in B, D and F for WT, α1100 and δ00, respectively, to confirm the effect of etomidate on eIPSCs. (G) Bar graph comparing the outward current induced by the bath application of etomidate (expressed as a change in I_{hold}) for WT (black bar, n = 8), α1100 (dark grey bar, n = 9) and δ00 (light grey bar, n = 7) VB neurons. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA, Tukey’s post hoc test.
curves was significantly increased in the presence of the anaesthetic (EA50: control = 170 ± 12 pA; + etomidate = 195 ± 12 pA, n = 12, P < 0.001). By contrast, although etomidate also hyperpolarized the resting $V_m$ and decreased the membrane IR of $\alpha^{10/0}$ VB neurons (Table 4), the consequent reduction of their excitability was less than for WT neurons (Fig. 7D–F). These findings are consistent with...
Etomidate inhibition of thalamocortical neurons

TABLE 4. Comparison of the effect of etomidate on the resting membrane potential ($V_{\text{m}}$) and input resistance of WT, $\alpha_1^{+}$, and $\delta^{0}$ VB neurons

|                  | WT ($n$ = 19) | $\alpha_1^{+}$ ($n$ = 12) | $\delta^{0}$ ($n$ = 11) |
|------------------|---------------|--------------------------|-------------------------|
| $V_{\text{m}}$ (mV) |                |                          |                         |
| Control          | $-71.7 \pm 0.8$ | $-71.7 \pm 0.8$          | $-74.6 \pm 0.6$         |
| $3 \mu$m etomidate | $-73.2 \pm 0.9^{***}$ | $-73.2 \pm 0.9^{***}$ | $-75.5 \pm 0.7^{*}$    |
| Input resistance  | $258 \pm 14$   | $193 \pm 11^{****}$      | $287 \pm 31$           |
|                  |                |                          | $275 \pm 27$           |

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, paired t-test.

Discussion

In this study, we investigated the relative contribution of synaptic and extrasynaptic GABA$_{A}$Rs to the etomidate-induced inhibition of neuronal activity in a network putatively involved in general anaesthetic mechanisms. Specifically, deletion of the $\delta$ subunit reduced the effect of etomidate on VB tonic inhibition. Consequently, the ability of etomidate to inhibit burst and tonic spiking was virtually abolished in $\delta^{0}$ mice, suggesting that etomidate facilitation of tonic inhibition exerts a dominant effect on TC cell output. Unexpectedly, deletion of the $\alpha_1$ subunit also reduced the impact of etomidate on VB tonic inhibition and the relay neuron I-O relationship, thus implicating the $\alpha_1$-GABA$_{A}$R population during anaesthetic actions in thalamus. Importantly, etomidate also greatly prolonged the duration of nRT burst-mediated phasic inhibition, by potentiating both synaptic and extrasynaptic GABA$_{A}$Rs. Thus, further to conventional phasic and tonic inhibition, burst-mediated spillover may represent a novel mechanism whereby anaesthetics can modulate circuit function.

While anaesthetics probably exert their behavioural effects by altering neuronal activity across multiple brain regions (Franks, 2008), human neuro-imaging studies have identified a consistent thalamic deactivation during anaesthetic-induced sedation and/or loss of consciousness (Isher et al., 1999; Alkire et al., 2000; White & Alkire, 2003; Hofbauer et al., 2004; Gili et al., 2013). Such studies are consistent with the canonical view of the thalamus as a sensory ‘gate’ that governs the transmission of multi-modal information to the cortex (Steriade, 2003). In vivo, anaesthetics may modulate thalamic activity directly by influencing the intrinsic excitability of resident thalamic neurons or indirectly by altering the activity of extrinsic excitatory inputs (e.g. descending cortico-thalamic, or ascending reticular activating system inputs). Indeed, single-unit recordings from cats showed a reduction of the spontaneous tonic firing rate of TC neurons by etomidate, alongside similar decreases in the neocortex and reticular formation (Andrada et al., 2012). Computer simulations utilizing thalamocortical network models have also provided important insights, revealing that elevated inhibition of cortical and thalamic neurons imposes a slowed, hyper-synchronous rhythm upon the thalamocortical loop that is reminiscent of electroencephalography dynamics during anaesthetized states (Talavera et al., 2009; Ching et al., 2010; Purdon et al., 2013). Collectively, such studies favour a co-ordinated action of anaesthetics across key interconnected networks, rather than a specific localized effect. Nevertheless, our data support the hypothesis that etomidate mediates at least a component of its actions by a direct reduction of TC neuron output, resulting from enhanced synaptic and extrasynaptic GABA$_{A}$R function. In agreement, propofol and the volatile agent isoflurane also inhibit relay neuron tonic spiking in a manner that is at least partially GABA$_{A}$R-dependent (Ying & Goldstein, 2005a,b; Jia et al., 2008).

That some general anaesthetics exert their spectrum of behavioural effects via a selective interaction with the GABA$_{A}$R is well established (Hales & Lambert, 1991; Franks & Lieb, 1994). In support, mutant mice harbouring point-mutated GABA$_{A}$Rs engineered to be etomidate-insensitive ($\beta_2$N265S; Belelli et al., 1997; Reynolds et al., 2003) or propofol- and etomidate-insensitive ($\beta_3$N265M; Pitsis et al., 2000; Jurd et al., 2003) display dramatically altered behavioural responses to these anaesthetics, revealing that specific anaesthetic behaviours can be assigned to individual GABA$_{A}$R populations. Specifically, the sedative and immobilizing effects of both etomidate and propofol are mediated by $\beta_2$- and $\beta_3$-containing receptors, respectively, whereas both receptor populations contribute to the hypnotic component (Jurd et al., 2003; Reynolds et al., 2003). However, these studies did not address which $\beta_2$- or $\beta_3$-expressing neuronal populations may be involved in the respective behaviours. Thus, it is noteworthy that the effects of etomidate on relay cell phasic and tonic currents are greatly involved in $\beta_2$N265S slices (Belelli et al., 2005). In light of the present evidence for a reduced etomidate-induced inhibition of relay neuron spiking in $\alpha_1^{0}$ and $\delta^{0}$ mice, such studies implicate synaptic ($\alpha_1[2\beta_2]$) and extrasynaptic ($\alpha_1[2\beta_2]$) GABA$_{A}$Rs as important molecular targets for the thalamic actions of this anaesthetic.

The effect of etomidate on VB tonic inhibition was virtually abolished in $\delta^{0}$ mice, leading to a reduced inhibitory effect on burst and tonic spiking. Such observations are consistent with the tonic conductance generating an inhibitory charge which greatly outweighs that produced by brief, spontaneous phasic inhibition. In agreement, computational studies utilizing a thalamocortical network model suggest that enhanced tonic inhibition is critical for the etomidate-induced depression of thalamic firing (Talavera et al., 2009). Thus, the significant effect of the $\alpha_1$ subunit deletion (albeit lesser than for the $\delta^{0}$) was unexpected. One potential interpretation...
suggests that a subpopulation of δ-GABA\textsubscript{A}Rs may contain the α\textsubscript{1} subunit instead of α\textsubscript{4}. Indeed, α\textsubscript{1} can form a functional partnership with the δ subunit in some hippocampal interneurons (Glykys \textit{et al.}, 2007). However, while α\textsubscript{1} subunit deletion abolishes spontaneous phasic inhibition in VB (Peden \textit{et al.}, 2008), we did not detect a significant reduction of baseline tonic inhibition, or the current induced by the δ-selective agonist THIP (4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol), which does not discriminate between α\textsubscript{1}/βδ and
Etomidate inhibition of thalamocortical neurons

**Table 5. Comparison of the effect of etomidate on the input-output relationship of WT, z1100 and δ100 VB neurons**

|          | Etomidate-induced change in EA50 (pA) |
|----------|--------------------------------------|
| WT (n = 12) | 25 ± 4                               |
| z1100 (n = 11) | 12 ± 5*                              |
| δ100 (n = 19)  | 0 ± 6**                               |

*P < 0.05, **P < 0.01, vs. WT, one-way ANOVA, Tukey’s post-hoc test.

**Electrophysiology**

z4β2 receptors (B. Ebert, personal communication; Herd et al., 2009), suggesting that z4β2 receptors are not abundantly expressed in VB neurons. Alternatively, the loss of on-going spontaneous phasic inhibition, which is robustly prolonged by etomidate in WT neurons, may partially account for the reduced effect of the anaesthetic on spike discharge for z1100 relay neurons. Additionally, a substantial pool of z1β2 receptors may exist extrasynaptically (Kasugai et al., 2010). While this receptor population does not appear to contribute to baseline tonic inhibition, etomidate, which increases GABAAR channel open probability in response to low GABA concentrations (Yang & Uchida, 1996), may enhance the activation of extrasynaptic z1β2 receptors by ambient GABA. Finally, we cannot exclude that direct activation of z1β2 receptors by etomidate (Hill-Venning et al., 1997) may influence VB neuron excitability.

Using paired nRT–VB recordings, we recently reported that peri/extrasynaptic z4β2 receptors are recruited during nRT burst firing, leading to a substantial prolongation of burst-mediated phasic inhibition (Herd et al., 2013). In support of this, despite the absence of synaptic GABAARs, we observed a residual eIPSC in z1100 VB neurons, which was greatly potentiated by the δ-selective positive allosteric modulator DS2 (Herd et al., 2013). Here, we observed a similar potentiation of the residual eIPSC upon application of etomidate to z1100 slices. Consequently, the remarkable ability of the residual eIPSPs to suppress tonic spiking of z1100 neurons was greatly prolonged by etomidate. In z4100 and δ100 mice, eIPSCs are shorter due to the abolished spill-over component, and are insensitive to DS2, consistent with the loss of z4β2 receptors (Herd et al., 2013). In contrast to DS2, in δ100 recordings, etomidate significantly prolonged eIPSCs and therefore the eIPSP-induced suppression of tonic spiking. Curiously, for the latter paradigm, the duration of spike suppression induced by the eIPSP in the presence of etomidate was not significantly different from WT in either z1100 or δ100 neurons (Fig. 3D), despite a clear effect of both gene deletions under control conditions (Fig. 2D). In current-clamp recordings the duration of IPSPs is determined partially by the kinetic properties of GABAARs, but also by the ensuing activation of voltage-dependent conductances (e.g. Ih and Ih), which may act to truncate the IPSP time course (Thomson et al., 2000). Thus, we speculate that the duration of the IPSP may be maximized in the presence of the anaesthetic and that this ‘ceiling effect’ may be achieved via the potentiation of either synaptic or extrasynaptic GABAARs in the absence of the complementary receptor population. Nevertheless, the results suggest that etomidate facilitates burst-mediated inhibition via a combined action at synaptic and peri/extrasynaptic GABAARs, leading to an amplified inhibitory effect on VB tonic firing.

As noted above, the strength of synaptic inhibition arising from nRT neurons interacts with intrinsic voltage-dependent conductances to control the timing of post-inhibitory rebound bursts, and thus the period and synchrony of thalamus-dependent oscillations, which prevail in the unconscious brain (Huguenard & McCormick, 2007). In addition to an enhanced tonic inhibition, which induces a membrane hyperpolarization that is likely to favour burst firing (Cope et al., 2005), etomidate also delayed the timing of post-inhibitory rebound burst firing by prolonging the IPSP. Given the importance of burst firing during thalamocortical rhythmogenesis, the etomidate-induced increase of IPSP duration may therefore contribute to the slowed oscillatory activity of the anaesthetized brain.

Our *in vitro* data, together with a computational study (Talavera et al., 2009), suggest that the etomidate-induced inhibition of TC output is dependent on synaptic and extrasynaptic GABAARs. Thus, it is surprising that deletion of z1, z4 or δ subunits exerts little or no influence on the sedative or hypnotic actions of etomidate (Mihalek et al., 1999; Kralic et al., 2003; Iyer et al., 2013). However, the interpretation of behavioural data obtained from mice harbouring global GABAAR subunit deletions is complicated by the non-uniform up-regulation of alternative GABAAR isofoms following subunit loss (Sur et al., 2001; Kralic et al., 2002a,b; Peng et al., 2002). This caveat is exemplified by studies investigating the sub-unit-dependence of benzodiazepine-induced behaviours; mice expressing a benzodiazepine-insensitive z1 subunit (H101R) are resistant to the sedative effects of diazepam (Rudolph et al., 1999; McKernan et al., 2000), yet z1100 mice exhibit enhanced diazepam-induced sedation (Kralic et al., 2002b). Thus, caution is warranted when comparing results from a slice preparation demonstrating minimal functional GABAAR compensation to behavioural studies underpinned by complex interactions between multiple brain networks subject to varying degrees of compensation. We note that an as yet unidentified neuronal adaptation (e.g. as described by Brickley et al., 2001) is likely to compensate for the loss of tonic or phasic inhibition in relay neurons, as demonstrated by the lack of any significant alteration in membrane IR or the I-O relationship in the mutant mice. Crucially, however, such adaptations do not appear to include upregulation of the remaining palette of GABAAR subunits (Kralic et al., 2006; Peden et al., 2008; Herd et al., 2009).

In summary, we have shown that etomidate reduces the electrical excitability of thalamocortical relay neurons via a specific interaction with synaptic and extrasynaptic GABAARs. Given the established role of the thalamus in arbitrating conscious state transitions, our results support the putative role of these distinct thalamic GABAAR populations in general anaesthetic actions. Finally, we suggest that burst-mediated spill-over, a kinetically intermediate form of inhibition that bridges the kinetic extremes of fast phasic and slow tonic inhibition, represents a novel means by which GABA-modulatory anaesthetics may influence the relay of sensory information from thalamus to cortex.

**Acknowledgements**

This work was supported by an Epilepsy Research UK fellowship (M.B.H., F1001), the BBSRC (D.B. & J.J.I.L. Grant CS09923), Tenovus Scotland (M.B.H., D.B. & J.J.I.L.) and the Anonymous Trust (M.B.H., D.B. & J.J.I.L.). We thank Dr Bjørke Ebert (Lundbeck) for sharing unpublished data, and Dr Thomas Rosahl (Merck) and Professor Gregg Homanics (University of Pittsburgh) for provision of the z1100 and δ100 mice, respectively. The authors declare no competing financial interests.

**Abbreviations**

ANOVA, analysis of variance; DMSO, dimethyl sulfoxide; DS2, δ-selective compound 2; EA50, excitatory current required for half maximal spike frequency; ECS, extracellular solution; GABAAR, extrasynaptic γ-aminobutyric acid, type A receptor; eIPSC, evoked IPSC; eIPSP, evoked IPSP; Erev, reversal potential; GABA, γ-aminobutyric acid; GABAAR, γ-aminobutyric acid, type A receptor; GABAβγ, γ-aminobutyric acid, type B receptor; Ih, current mediated by hyperpolarization-activated, cyclic nucleotide-gated cation channels; I-O, input–output relationship; IPSC, inhibitory postsynaptic...
current; IPSP, inhibitory postsynaptic potential; IR, membrane input resistance; ISL, inter-spike interval; Ir, current mediated by low threshold T-type Ca2+ channel; IPSC, inhibitory postsynaptic current; mGluR, metabotropic glutamate receptor; TC, thalamocortical; VB, ventrobasal thalamic nucleus; WT, wild-type; x1 ε90, x1 subunit knock-out mouse; x1-GABA_A; x2 subunit-containing GABA_A receptor; β3δ256M, asparagine to methionine mutation at position 265 of the GABA_A receptor β3 subunit; β2δ265S, asparagine to serine mutation at position 265 of the GABA_A receptor β2 subunit; δω90, δ subunit knock-out mouse; δ-GABA_A; δ subunit-containing GABA_A receptor; τm, weighted decay time constant.

References

Alikre, M.T., Haer, R.J. & Fallon, J.H. (2000) Toward a unified theory of narcosis: brain imaging evidence for a thalamocortical switch as the neurophysiologic basis of anesthetic-induced unconsciousness. Conscious. Cogn., 9, 370–386.

Andrada, J., Livingston, P., Lee, B.J. & Antognini, J. (2012) Propofol and containing GABA A receptor; Glykys, J., Peng, Z., Chandra, D., Homanics, G.E., Houser, C.R. & Mody, I. (2002a) Molecular and pharmacological characterization of GABA(A) receptor alpha subunit knock-out mouse. J. Pharmacol. Exp. Ther., 302, 1037–1045.

Baker, R.B., Brown, A.R., Lee, B.J. & Antognini, J. (2013) Extrasynaptic GABA_A receptors couple presynaptic activity to postsynaptic inhibition in the somatosensory thalamus. J. Neurosci., 33, 14850–14868.

Belelli, D., Callachan, H., Hill-Venning, C., Peters, J.A. & Lambert, J.J. (1996) Interaction of positive allosteric modulators with human D9orphila recombinant GABA_A receptors expressed in Xenopus laevis oocytes. Brit. J. Pharmacol., 118, 563–576.

Belelli, D., Lambert, J.J., Peters, J.A., Wafford, K. & Whiting, P.J. (1997) The general anesthetic etomidate modulates thalamic, and reticular formation neurons during anesthetic-induced unconsciousness. Anesth. Analg., 114, 661–669.

Belelli, D., Callachan, H., Hill-Venning, C., Peters, J.A. & Lambert, J.J. (1997) Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. J. Pharmacol. Exp. Ther., 281, 607–614.

Belelli, D., Callachan, H., Hill-Venning, C., Peters, J.A. & Lambert, J.J. (2009) Inhibition of GABA_A receptors couple presynaptic activity to postsynaptic inhibition in the somatosensory thalamus. J. Neurosci., 33, 14850–14868.

Belelli, D., Callachan, H., Hill-Venning, C., Peters, J.A. & Lambert, J.J. (1997) Subunit-dependent interaction of the general anaesthetic etomidate with the gamma-aminobutyric acid type A receptor. Brit. J. Pharmacol., 120, 749–756.

Bonin, R.P. & Orser, B.A. (2008) GABA_A receptor subtypes underlying general anaesthesia. Eur. J. Neurosci., 29, 1177–1187.

Bonin, R.P., Brown, A.R. & Orser, B.A. (2012) GABA_A receptors in thalamocortical; VB, ventrobasal complex; γ, membrane potential; WT, wild-type; x1 ε90, x1 subunit knock-out mouse; x1-GABA_A; x2 subunit-containing GABA_A receptor; β3δ256M, asparagine to methionine mutation at position 265 of the GABA_A receptor β3 subunit; β2δ265S, asparagine to serine mutation at position 265 of the GABA_A receptor β2 subunit; δω90, δ subunit knock-out mouse; δ-GABA_A; δ subunit-containing GABA_A receptor; τm, weighted decay time constant.

Brickley, S.G., Revilla, V., Cull-Candy, S.G., Wisden, W. & Farrant, M. (2001) Adaptive regulation of neuronal excitability by a voltage-independent potassium conductance. Nature, 409, 88–92.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.

Cope, D.W., Hughes, S.W. & Crunelli, V. (2005) GABA_A receptor-mediated tonic inhibition in thalamic VB neurons. J. Neurophysiol., 94, 4491–4501.
Peden, D.R., Petitjean, C.M., Herd, M.B., Durakoglugil, M.S., Rosahl, T.W., Wafford, K., Homanics, G.E., Bellesi, D., Fritschy, J.M. & Lambert, J.J. (2008) Developmental maturation of synaptic and extrasynaptic GABAA receptors in mouse thalamic ventrobasal neurons. *J. Physiol.*, **586**, 965–987.

Peng, Z., Hauer, B., Mihalek, R.M., Homanics, G.E., Sieghart, W., Olsen, R.W. & Houser, C.R. (2002) GABAA receptor changes in δ subunit-deficient mice: altered expression of γ4 and γ2 subunits in the forebrain. *J. Comp. Neurol.*, **446**, 179–197.

Pistis, M., Bellesi, D., McGurk, K., Peters, J.A. & Lambert, J.J. (1999) Complementary regulation of anaesthetic activation of human (γ6)β3γ2L and Drosophila (RDL) GABA receptors by a single amino acid residue. *J. Physiol.*, **515**(Pt 1), 3–18.

Purdon, P.L., Pierce, E.T., Prerau, M.J., Walsh, J.L., Wong, K.F., Salazar-Gomez, A.F., Harrell, P.G., Sampson, A.L., Cimenser, A., Ching, S., Kopell, N.J., Tavares-Stoeckel, C., Habeeb, K., Merhar, R. & Brown, E.N. (2013) Electroencephalogram signatures of loss and recovery of consciousness from propofol. *Proc. Natl. Acad. Sci. USA*, **110**, E1142–E1151.

Reynolds, D.S., Rosahl, T.W., Cirone, J., O’Meara, G.F., Haythornthwaite, A., Newman, R.J., Myers, J., Sur, C., Howell, O., Rutter, A.R., Attack, J., Macaulay, A.J., Hadingham, K.L., Hutson, P.H., Bellesi, D., Lambert, J.J., Dawson, G.R., McKernan, R., Whiting, P.J. & Wafford, K.A. (2003) Sedation and anesthesia mediated by distinct GABAA receptor isoforms. *J. Neurosci.*, **23**, 8608–8617.

Rudolph, U. & Antkowiak, B. (2004) Molecular and neuronal substrates for general anaesthetics. *Nat. Rev. Neurosci.*, **5**, 709–720.

Rudolph, U., Crestani, F., Benke, D., Brunig, I., Benson, J.A., Fritschy, J.M., Martin, J.R., Bluthmann, H. & Mohler, H. (1999) Benzodiazepine actions mediated by specific gamma-aminobutyric acidA receptor subtypes. *Nature*, **401**, 796–800.

Steriade, M. (2003) Neuronal Substrates of Sleep and Epilepsy, Cambridge University Press, Cambridge.

Steriade, M., McCormick, D.A. & Sejnowski, T.J. (1993) Thalamocortical oscillations in the sleeping and aroused brain. *Science*, **262**, 679–685.

Sur, C., Wafford, K.A., Reynolds, D.S., Hadingham, K.L., Bromidge, F., Macaulay, A., Collinson, N., O’Meara, G., Howell, O., Newman, R., Myers, J., Attack, J.R., Dawson, G.R., McKernan, R.M., Whiting, P.J. & Rosahl, T.W. (2001) Loss of the major GABAA receptor subtype in the brain is not lethal in mice. *J. Neurosci.*, **21**, 3409–3418.

Talavera, J.A., Esser, S.K., Amzica, F., Hill, S. & Antognini, J.F. (2009) Modeling the GABAergic action of etomidate on the thalamocortical system. *Anesth. Analg.*, **108**, 160–167.

Thomson, A.M., Bannister, A.P., Hughes, D.I. & Pawelzik, H. (2000) Differential sensitivity to Zolpidem of IPSPs activated by morphologically identified CA1 interneurons in slices of rat hippocampus. *Eur. J. Neurosci.*, **12**, 425–436.

Tretter, V., Hauer, B., Nusser, Z., Mihalek, R.M., Hoger, H., Homanics, G.E., Somogyi, P. & Sieghart, W. (2001) Targeted disruption of the GABAA receptor δ subunit gene leads to an up-regulation of γ2 subunit-containing receptors in cerebellar granule cells. *J. Biol. Chem.*, **276**, 10532–10538.

Uchida, I., Kamatchi, G., Burt, D. & Yang, J. (1995) Etomidate potentiation of GABAA receptor gated current depends on the subunit composition. *Neurosci. Lett.*, **185**, 203–206.

Wafford, K.A., van Niel, M.B., Ma, Q.P., Horridge, E., Herd, M.B., Peden, D.R., Bellesi, D. & Lambert, J.J. (2009) Novel compounds selectively enhance δ subunit containing GABAA receptors and increase tonic currents in thalamus. *Neuropharmacology*, **56**, 182–189.

White, N.S. & Alkire, M.T. (2003) Impaired thalamocortical connectivity in humans during general-anesthetic-induced unconsciousness. *NeuroImage*, **19**, 402–411.

Yang, J. & Uchida, I. (1996) Mechanisms of etomidate potentiation of GABAA receptor-gated currents in cultured postnatal hippocampal neurons. *Neuroscience*, **73**, 69–78.

Ying, S.W. & Goldstein, P.A. (2005a) Propofol-block of SK channels in reticular thalamic neurons enhances GABAergic inhibition in relay neurons. *J. Neurophysiol.*, **93**, 1935–1948.

Ying, S.W. & Goldstein, P.A. (2005b) Propofol suppresses synaptic responsiveness of somatosensory relay neurons to excitatory input by potentiating GABAA receptor chloride channels. *Mol. Pain*, **1**, 2.